Medical Devices

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Syndromic Multiplex Diagnostic Market – Industry Trends and Forecast to 2029

Medical Devices | Published Report | May 2022 | MEA | 350 Pages | No of Tables: 76 | No of Figures: 43

Report Description

Middle East and Africa Syndromic Multiplex Diagnostic Market - By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others) Industry Trends and Forecast to 2029.


Market Definition and Insights

Syndromic multiplex diagnostic is a type of advanced diagnostic test utilised to detect infectious diseases such as respiratory infection, infective gastroenteritis, sexually transmitted infections, sepsis, and meningitis, among other types of infectious diseases. The syndromic multiplex diagnostic also helps the clinicians or hospitals to detect the symptoms and signs of the various types of diseases. This lets the health care providers provide the right treatment for the patients and offer more precise outcomes and care that can be performed more quickly.

Get Exclusive Sample Copy of this Report Here

Get Exclusive Sample Copy of this Report Here

Syndromic multiplex testing is used to diagnose many pathogens simultaneously. In the syndromic multiplex diagnostic, various types of reagents & consumables and instruments & accessories are used, which helps maintain accuracy and provide fast diagnosis results. These multiplex tests are rapidly diagnosed with certain infections, allowing clinical management decisions to be made promptly. The tests based on multiplex technology are known as test panels. The panels used in syndromic testing are designed to diagnose multiple diseases associated with the same or similar syndrome type. These panels help evaluate the cause of the disease at the point of care. Gastrointestinal panels and respiratory panels are the types of syndromic panels.

Syndromic multiplex testing utilizes the advanced technology of multiplex PCR which provides accurate and fast diagnostic results, with the help of the multiple panels used in syndromic multiplex diagnostic to provide diagnostic results within an hour. The new generations of syndromic multiplex can rapidly identify the common type of pathogens in the respiratory specimens, blood and cerebrospinal. The use of multiplex panels is associated with quicker turnaround time, reduction of other unnecessary laboratory tests, faster diagnosis and targeted treatment.

Data Bridge Market Research analyses that the Middle East and Africa syndromic multiplex diagnostic market will grow at a CAGR of 6.4% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others),  Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel and Others),  End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others),

Countries Covered

South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa

Market Players Covered

BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Prominex Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany)

Syndromic Multiplex Diagnostic Market Dynamics

Drivers

  • Rise in prevalence of infectious diseases

The rising incidence of infectious bacterial and viral diseases impacts the market's demand because, in the syndromic testing, multiplex real-time PCR technique and the syndromic approach are used for molecular diagnostics of infectious diseases.

  • Increasing awareness towards early diagnosis

People are getting more aware of the early diagnosis of diseases required for effective treatment. The multiplex diagnosis provides fast and accurate results; hence, the increase in demand for these instruments is driving the market's growth.

Opportunities

  • Development of Diagnostic Laboratories

Diagnostic laboratories play a central role in healthcare by providing accurate information, the foundation for effective care. The requirement of reliable, fast, and accurate test results is vital in emergency rooms, critical care centers, and other situations where treatment decisions must be based on the diagnostic results. Hence, the development of diagnostic laboratories is acting as opportunity for market growth.

  • Rising Diagnostic Healthcare Expenditure

The growing healthcare expenditure is expected to increase the availability of services and affordability for the population to opt for better and more precise diagnostic services to manage their diseases. The increase in healthcare expenditure ensures better availability of diagnostic services. Hence, huge health care expenditure is a favourable factor and is acting as an opportunity for the growth of the syndromic multiplex diagnostic market.

Restraint/Challenge

  • Explicit Limitation of Syndromic Multiplex Testing

The current limitations of syndromic multiplex diagnostic are that the molecular assays used in this application can identify a limited or few numbers of microbial targets, also the assays have moderate sensitivity, which may hamper the market growth.

Post COVID-19 Impact on Syndromic Multiplex Diagnostic market

COVID-19 has positively affected the market. Market players are launching different products for the detection of the SARS-CoV virus. There is an increase in approval of products by regulatory bodies after post COVID-19, which leads to an increase in market growth.

Recent Development

  • In December 2021, BD expanded its BD COR system to include a new MX instrument for molecular testing of infectious diseases. The MX instrument expands the platform and automates essential testing assays for women's health and STI testing using a multiplex PCR assay design. This has helped the company to increase its portfolio.

Syndromic Multiplex Diagnostic Market Scope

The syndromic multiplex diagnostic market is categorized into five segments: product and services, infection type, disease, panels type, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

  • Reagents & Consumables
  • Instruments, Software & Accessories
  • Services

Based on products and services, the Middle East and Africa syndromic multiplex diagnostic market is segmented into reagents & consumables, instruments, software & accessories and services.

Infection Type

  • Viral
  • Bacterial
  • Parasites
  • Fungal

Based on infection type, the Middle East and Africa syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites and fungal

Disease

  • Respiratory Infection
  • Gastroneteritis
  • Sexually Transmitted Infections
  • Sepsis
  • Meningitis
  • Others

Based on disease, the Middle East and Africa syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis meningitis and others

Panels Type

  • Respiratory Panel
  • GI-Enteric Panel
  • Sexually Transmitted Disease Panel
  • Blood-Sepsis Panel
  • Meningitis Panel
  • Others

Based on panels type, the Middle East and Africa syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel and others

End User

  • Hospitals
  • Clinical Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Others

Get Exclusive Sample Copy of this Report Here

Based on end user, the Middle East and Africa syndromic multiplex diagnostic market is segmented into clinical laboratories, hospitals, pharmaceutical & biotechnology companies, research institutes and others

Syndromic Multiplex Diagnostic Market Regional Analysis/Insights

The syndromic multiplex diagnostic market is analysed and market size insights and trends are provided by country, product and services, infection type, disease, panels type and end user as referenced above.

The countries covered in the report are South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.

South Africa syndromic multiplex diagnostic market is expected to grow due to an increase in the prevalence of infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.

Syndromic Multiplex Diagnostic Market Share Analysis

The syndromic multiplex diagnostic market competitive landscape provides details of a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Saudi Arabia presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the syndromic multiplex diagnostic market.

Some of the major players operating in the Middle East and Africa syndromic multiplex diagnostic market are BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc., Luminex Corporation. A DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid (A subsidiary of Danaher), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Biocartis, QuantuMDx Group Ltd., Prominex Inc., Curetis (A subsidiary of OpGen, Inc.), among others.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT AND SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021)

5 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES

6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES

6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING

6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS

6.2 RESTRAINTS

6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS

6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE

6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS

6.4 CHALLENGES

6.4.1 PRODUCT RECALLS

6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS

7 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES

7.1 OVERVIEW

7.2 REAGENTS & CONSUMABLES

7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES

7.4 SERVICES

8 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE

8.1 OVERVIEW

8.2 VIRAL

8.2.1 CORONAVIRUS

8.2.2 INFLUENZA VIRUS

8.2.3 ADENOVIRUS

8.2.4 RHINOVIRUS

8.2.5 ROTAVIRUS

8.2.6 OTHERS

8.3 BACTERIAL

8.3.1 PNEUMONIAE

8.3.2 BORDETELLA PERTUSSIS

8.3.3 STAPHYLOCOCCUS

8.3.4 OTHERS

8.4 PARASITES

8.5 FUNGAL

9 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE

9.1 OVERVIEW

9.2 RESPIRATORY INFECTIONS

9.3 GASTROENTERITIS

9.4 SEXUALLY TRANSMITTED INFECTIONS

9.5 SEPSIS

9.6 MENINGITIS

9.7 OTHERS

10 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE

10.1 OVERVIEW

10.2 RESPIRATORY PANEL

10.3 GI-ENTERIC PANEL

10.4 SEXUALLY TRANSMITTED DISEASE PANEL

10.5 BLOOD-SEPSIS PANEL

10.6 MENINGITIS PANEL

10.7 OTHERS

11 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 CLINICAL LABORATORIES

11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.5 RESEARCH INSTITUTES

11.6 OTHERS

12 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION

12.1 MIDDLE EAST AND AFRICA

12.1.1 SOUTH AFRICA

12.1.2 SAUDI ARABIA

12.1.3 U.A.E

12.1.4 ISRAEL

12.1.5 EGYPT

12.1.6 REST OF MIDDLE EAST AND AFRICA

13 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMÉRIEUX SA)

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.2 F. HOFFMANN-LA ROCHE LTD

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.3 LUMINEX CORPORATION. A DIASORIN COMPANY

15.3.1 COMPANY SNAPSHOT

15.3.2 RECENT FINANCIALS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENT

15.4 CEPHEID (A SUBSIDIARY OF DANAHER)

15.4.1 COMPANY SNAPSHOT

15.4.2 RECENT FINANCIALS

15.4.3 COMPANY SHARE ANALYSIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENTS

15.5 QIAGEN

15.5.1 COMPANY SNAPSHOT

15.5.2 RECENT FINANCIALS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENT

15.6 ABBOTT

15.6.1 COMPANY SNAPSHOT

15.6.2 REVENUE ANALYSIS

15.6.3 PRODUCT PORTFOLIO

15.6.4 RECENT DEVELOPMENT

15.7 AKONNI BIOSYSTEMS, INC.

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 APPLIED BIOCODE, INC.

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 BD

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.1 BIOCARTIS

15.10.1 COMPANY SNAPSHOT

15.10.2 REVENUE ANALYSIS

15.10.3 PRODUCT PORTFOLIO

15.10.4 RECENT DEVELOPMENT

15.11 BIO-RAD LABORATORIES, INC.

15.11.1 COMPANY SNAPSHOT

15.11.2 REVENUE ANALYSIS

15.11.3 PRODUCT PORTFOLIO

15.11.4 RECENT DEVELOPMENT

15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH)

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENT

15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.)

15.13.1 COMPANY SNAPSHOT

15.13.2 RECENT FINANCIALS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 HOLOGIC, INC.

15.14.1 COMPANY SNAPSHOT

15.14.2 RECENT FINANCIALS

15.14.3 PRODUCT PORTFOLIO

15.14.4 RECENT DEVELOPMENT

15.15 MIRXES PTE LTD.

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 NANŌMIX, INC.

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.17 PROMINEX INC.

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENT

15.18 QUANTUMDX GROUP LTD.

15.18.1 COMPANY SNAPSHOT

15.18.2 PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENTS

15.19 SEEGENE INC.

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUE ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENTS

15.2 SIEMENS HEALTHCARE GMBH

15.20.1 COMPANY SNAPSHOT

15.20.2 RECENT FINANCIALS

15.20.3 PRODUCT PORTFOLIO

15.20.4 RECENT DEVELOPMENT

15.21 THERMOFISHER SCIENTIFIC INC.

15.21.1 COMPANY SNAPSHOT

15.21.2 RECENT FINANCIALS

15.21.3 PRODUCT PORTFOLIO

15.21.4 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

List of Table

TABLE 1 COST OF THE PRODUCT

TABLE 2 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 42 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 43 SOUTH AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 44 SOUTH AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 45 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 46 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 47 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 48 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 49 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 50 SAUDI ARABIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 51 SAUDI ARABIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 52 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 53 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 54 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 55 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 56 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 57 U.A.E VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 58 U.A.E BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 59 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 60 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 61 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 62 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 63 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 64 ISRAEL VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 65 ISRAEL BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 66 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 67 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 68 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 69 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 70 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 71 EGYPT VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 72 EGYPT BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 73 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 74 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 75 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 REST OF MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD

FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA

FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE

FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019

FIGURE 18 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021

FIGURE 19 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029)

FIGURE 21 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021

FIGURE 23 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029)

FIGURE 25 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021

FIGURE 27 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029)

FIGURE 29 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE

FIGURE 30 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021

FIGURE 31 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION)

FIGURE 32 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029)

FIGURE 33 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE

FIGURE 34 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021

FIGURE 35 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 36 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021)

FIGURE 39 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021)

FIGURE 40 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029)

FIGURE 43 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)

View Infographics

FIGURE 1 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD

FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA

FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE

FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019

FIGURE 18 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021

FIGURE 19 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029)

FIGURE 21 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021

FIGURE 23 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029)

FIGURE 25 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021

FIGURE 27 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029)

FIGURE 29 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE

FIGURE 30 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021

FIGURE 31 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION)

FIGURE 32 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029)

FIGURE 33 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE

FIGURE 34 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021

FIGURE 35 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 36 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021)

FIGURE 39 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021)

FIGURE 40 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029)

FIGURE 43 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19